Formaldehyde
Brand names: Veracur
Formaldehyde is a topical agent used in dermatology chiefly for the treatment of cutaneous warts, including plantar warts, and as a skin-hardening agent.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a chemical caustic and protein cross-linking agent that denatures keratin and macerates or destroys infected hyperkeratotic tissue.
Prescribing in practice
- It is corrosive and must be confined to the lesion; protect surrounding healthy skin and avoid mucous membranes, the face and broken skin to prevent chemical burns.
- It is a recognised contact sensitiser, so discontinue if allergic contact dermatitis develops.
- It is not suitable for use on mosaic warts of the soles in the same way as solitary lesions and should be used with particular care in diabetes or peripheral arterial disease.
Monitoring
No laboratory monitoring is required; review the lesion response and inspect surrounding skin for irritation or sensitisation.
Counselling the patient
- Apply only to the wart and protect the surrounding skin, for example with soft paraffin.
- Stop and seek advice if the skin becomes painful, blistered or develops a rash.
- Keep away from the eyes, mouth and healthy skin.
Evidence & guidelines
Topical keratolytic and caustic agents are long-standing options for cutaneous warts; most warts also resolve spontaneously over time.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD